Daunorubicin-Cytarabine Liposome (Vyxeos) — CPB 0921 | AETNA Coverage Update

Aetna modified CPB 0921 for daunorubicin-cytarabine liposome (Vyxeos), effective September 26, 2025. Here's what billing teams need to know before submitting claims under J9153.

Aetna, a CVS Health company, updated its Vyxeos coverage policy under CPB 0921 Aetna system, refining the medical necessity criteria for induction, re-induction, and consolidation therapy across therapy-related AML, AML arising from MDS/CMML, and AML with MDS-related cytogenetic changes. The primary billing codes affected are HCPCS J9153 (injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine) and CPT codes 96413–96417 for chemotherapy administration. If your oncology or hematology billing team submits Vyxeos claims to Aetna, this update changes the specific indications that qualify for reimbursement — and the ones that don't.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Daunorubicin-Cytarabine Liposome (Vyxeos)
Policy Code	CPB 0921
Change Type	Modified
Effective Date	September 26, 2025
Impact Level	High
Specialties Affected	Hematology/Oncology, Inpatient Hospital Billing, Infusion Centers
Key Action	Verify AML subtype and treatment phase against updated CPB 0921 criteria before submitting J9153 claims

---

Aetna Vyxeos Coverage Criteria and Medical Necessity Requirements 2025

The updated Aetna Vyxeos coverage policy under CPB 0921 separates coverage into three distinct clinical scenarios. Each one has its own medical necessity threshold. Get the diagnosis and treatment phase right before you bill J9153, or the claim will deny.

Induction Therapy

Aetna covers Vyxeos for treatment induction when the member is a candidate for intensive induction therapy and has one of the following AML subtypes:

#	Covered Indication Copy
1	Therapy-related AML (t-AML), excluding core binding factor-AML (CBF-AML)
2	AML arising from antecedent MDS or chronic myelomonocytic leukemia (CMML)
3	AML with cytogenetic changes consistent with MDS — previously classified as AML-MRC

CBF-AML is explicitly excluded from induction coverage. If your oncologist's documentation doesn't specify the AML subtype and rule out CBF-AML, your prior authorization request and your claim are both at risk.

Consolidation Therapy

For consolidation, Aetna broadens the qualifying population slightly. Coverage applies to members with poor-risk AML — with or without TP53 mutation or del17p abnormality — plus the same three subtypes covered under induction.

The addition of poor-risk AML with TP53 mutation or del17p for consolidation is the most clinically significant part of this update. These are high-risk patients where Vyxeos is increasingly standard. Document the cytogenetic and molecular findings explicitly in your prior authorization request.

Re-Induction Therapy

Vyxeos is covered for re-induction after cytarabine-based induction — but only as a preferred option if it was used in the initial induction. Coverage applies when the member has residual disease and the AML subtype is t-AML (excluding CBF-AML and acute promyelocytic leukemia/APL), AML from antecedent MDS/CMML, or AML with MDS-related cytogenetic changes.

APL is explicitly excluded from re-induction coverage under this policy. Document treatment history carefully. If Vyxeos wasn't used in the initial induction cycle, it's no longer a preferred agent at re-induction — and that distinction matters for prior authorization.

Continuation of Therapy

Aetna covers continuation of Vyxeos therapy up to a total of two cycles for induction (including re-induction) and up to two cycles for consolidation. Continuation requires no evidence of unacceptable toxicity for induction cycles, and no evidence of disease progression or unacceptable toxicity for consolidation cycles. Document each cycle's response and tolerability in the chart — you'll need it if Aetna requests medical records.

---

Aetna Vyxeos Exclusions and Non-Covered Indications

Aetna's coverage policy is direct: all indications not explicitly listed in sections IA, IB, or IC are considered experimental, investigational, or unproven.

That's a short list of covered uses. CBF-AML is excluded from induction and re-induction. APL is excluded from re-induction. Any use of Vyxeos outside of the three defined scenarios — regardless of clinical rationale — will not get covered.

Don't submit J9153 for off-label AML subtypes expecting a favorable review. Aetna has drawn a clear line here. If your oncologist believes Vyxeos is medically necessary for a subtype not listed, that's a peer-to-peer appeal conversation — not a billing workaround.

---

Coverage Indications at a Glance

---

Aetna Vyxeos Billing Guidelines and Action Items 2025

The effective date of September 26, 2025, means this policy is already active. If your team hasn't updated workflows to match the new CPB 0921 criteria, you're billing under outdated rules right now.

Here are your action items:

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Vyxeos Under CPB 0921

Covered HCPCS Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
J9153	HCPCS	Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine

J9153 is the primary drug billing code for Vyxeos. Every unit represents 1 mg daunorubicin / 2.27 mg cytarabine. A single-dose vial contains 44 mg daunorubicin and 100 mg cytarabine — calculate your units carefully before submitting.

CPT Codes for Chemotherapy Administration

These codes cover the infusion service. Vyxeos is administered over 90 minutes via IV infusion. Your administration billing will typically anchor on 96413 with 96415 for additional hours. Use the full code set based on actual infusion time and service complexity.

Key ICD-10-CM Diagnosis Codes

Use the most specific ICD-10 code your documentation supports. Submitting D46.9 when cytogenetic results support a more specific MDS subtype code is a common claim denial trigger under payer audits.

---